Low-dose glucagon to prevent low blood sugar during exercise in type 1 diabetes
Tests low-dose glucagon before exercise in adults with type 1 diabetes using automated insulin delivery.
Key facts
- Who runs it
- Steno Diabetes Center Copenhagen
- Where
- Herlev, DenmarkSee the site
- Trial code
- Registry title
- The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People with Type 1 Diabetes
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 18 people, planned
- Started
- 10 Apr 2026
- Expected to end
- 1 May 2027
- Type of study
- Interventional
- Record updated
- 16 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes who use an automated insulin delivery system. It tests low-dose glucagon before exercise after a meal.
- Age
- Older than 18 years
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes for more than 2 years.
- Earlier treatment
- Must have used an automated insulin delivery system for 3 months or more. Must have been treated with NovoRapid or Fiasp for at least one week before joining.
Main reasons for not taking part
- Allergy or past allergic reaction to lactose or glucagon
- Pheochromocytoma, insulinoma or gastroparesis
- Women of childbearing age who are pregnant, breast-feeding, planning pregnancy or not using adequate contraception
- Other medical or psychological conditions that the investigator judges make taking part unsuitable
- Cannot understand the information or give informed consent
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age more than 18 years old
- Type 1 diabetes > 2 years
- Use of automated insulin delivery system for equal to or more than 3 months
- Treated with NovoRapid or Fiasp for at least one week priro to enrolment
- Proefficiency in carbohydrate counting
Who cannot take part
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrolment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (>12 months since last period) are not required to use contraception)
- Allergies to lactose or glucagon
- Known or suspected allergies to glucagon or related products
- History of hypersensitivity or allergic reaction to glucagon or lactose
- Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation
- Patients with diagnosed pheochromocytoma, insulinoma or gastroparesis
- Lack of compliance with key study procedures at the discretion of the investigator
- Inability to understand the individual information and to give informed consent
Where in Denmark
- Steno Diabetes Center CopenhagenHerlev, DenmarkTaking people
About the trial
What the trial wants to find out
To evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People with Type 1 Diabetes
- Plain-language title
- Low-dose glucagon to prevent low blood sugar during exercise in type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 16 March 2026